Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1 12Phase 3 9Phase 1/2 4Phase 4 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 4Active not recruiting 3Withdrawn 1Completed 1

Sponsor Class

OTHER 5NETWORK 2INDUSTRY 2

Study Type

Interventional 9

Sponsor

Cancer Type

Genitourinary 9

Conditions

Prostatic Neoplasms 9Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer Non-Metastatic 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Genital Diseases, Male 1Biochemically Recurrent Prostate Cancer 1Adenocarcinoma 1

Interventions

Prednisone 53Radiotherapy 52Docetaxel 51Leuprolide 48Goserelin 47bicalutamide 45enzalutamide 28acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27Androgen Antagonists 27Flutamide 24Triptorelin Pamoate 22apalutamide 18Gonadotropin-Releasing Hormone 18Abiraterone Acetate 17Radiation 15abiraterone 14Zoledronic Acid 14Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 12Prednisolone 11luprolide acetate gel depot 10darolutamide 9Radiosurgery 9cabazitaxel 8Standard of Care 8Specimen Handling 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Estramustine 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

9 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Neoplasms × darolutamide × Clear all
NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT04136353 2026-05-06

DASL-HiCaP

University of Sydney

Phase 3 Active not recruiting
1,100 enrolled
Genitourinary

Prostatic Neoplasms

NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04736199 2026-02-27

ARANOTE

Bayer

Phase 3 Completed
669 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT06625970 2025-06-26

PEACE 7

UNICANCER

Phase 3 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT05116475 2024-03-12

ALADDIN

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Phase 3 Recruiting
152 enrolled
Genitourinary

Prostatic Neoplasms

NCT06177015 2023-12-26

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

The First Affiliated Hospital with Nanjing Medical University

Phase 3 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

NCT05771896 2023-09-14

CARE

GenesisCare USA

Phase 3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡